NURECA LIMITED
NURECA · General/Diversified · NSE
₹266
Current Market Price
Fair Value (DCF)
₹99
Margin of Safety
-62.7%
Updated 1h ago
YieldIQ Score
22/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
26%
ROE
—
Debt/Equity
0.03
WACC
11.1%
Market Cap
₹254 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
90.0%
Return on capital employed
EV / EBITDA
42.0×
Enterprise multiple
Debt / EBITDA
0.8×
Leverage vs earnings
Interest Coverage
4.4×
EBIT covers interest
Current Ratio
15.32×
Short-term liquidity
Asset Turnover
0.52×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-24.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹266.37
Bear case
₹2.45
MoS -10772.2%
Base case
₹99.26
MoS -168.4%
Bull case
₹104.22
MoS -155.6%
Ratio Trends
NURECA · last 4 annual periods
ROE
0.4%
ROCE
2.0%
Operating Margin
—
Debt / Equity
0.03×
PE
29.0×
EV / EBITDA
20.7×
Historical Financials
NURECA · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹256 Cr | ₹111 Cr | ₹91.9 Cr | ₹110 Cr | -24.6% |
| EBITDA | ₹62.9 Cr | ₹-8.0 Cr | ₹0.1 Cr | ₹4.1 Cr | -59.9% |
| EBIT | — | — | — | — | — |
| PAT | ₹45.0 Cr | ₹-8.3 Cr | ₹-1.8 Cr | ₹0.8 Cr | -73.4% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹1.4 Cr | ₹10.2 Cr | ₹-2.7 Cr | ₹-19.1 Cr | — |
| CapEx | ₹-6.0 Cr | ₹-0.4 Cr | ₹-1.1 Cr | ₹-4.3 Cr | — |
| FCF | ₹-4.6 Cr | ₹9.8 Cr | ₹-3.8 Cr | ₹-23.4 Cr | — |
| Total Assets | ₹219 Cr | ₹207 Cr | ₹205 Cr | ₹210 Cr | -1.4% |
| Total Debt | ₹4.4 Cr | ₹3.3 Cr | ₹2.5 Cr | ₹5.0 Cr | +4.1% |
| Shareholders' Equity | ₹203 Cr | ₹195 Cr | ₹193 Cr | ₹194 Cr | -1.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NURECA vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| UNIVPHOTO UNIVPHOTO | — | — | Pending | 10.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NURECA in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NURECA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NURECA →
Compare
Head-to-head with peers
Compare NURECA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NURECANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.